样式: 排序: IF: - GO 导出 标记为已读
-
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-13 Aalam Sohal, Kris V. Kowdley
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease associated with inflammation, fibrosis, and destruction of intra- and extrahepatic bile ducts. Despite substantial recent...
-
LESSONS LEARNED from EARLY-STAGE CLINICAL TRIALS for DIABETIC NEPHROPATHY Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-11 Marc Rendell
The evolution of treatment for diabetic nephropathy illustrates how basic biochemistry and physiology have led to new agents such as SGLT2 inhibitors and mineralocorticoid blockers. Conversely, cli...
-
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-06 Jonathan D. Greenzaid, Lina J. Chan, Brittany M. Chandani, Nicholas R. Kiritsis, Steven R. Feldman
Atopic dermatitis (AD) is a common inflammatory cutaneous disease that arises due to dysregulation of the Th2 immune response, impaired skin barrier integrity, and dysbiosis of the skin and gut mic...
-
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-06 David L. Paterson
Antimicrobial resistance is a major threat to modern healthcare, and it is often regarded that the antibiotic pipeline is ‘dry.’Antimicrobial agents active against Gram negative bacilli in Phase I,...
-
Investigational drugs for the treatment of dysmenorrhea Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-04 Amelia K. Mardon, Lucy Whitaker, Toobah Farooqi, Jane Girling, Claire Henry, Carolyn Ee, Jordan Tewhaiti-Smith, Mike Armour
Dysmenorrhea is the most common cause of gynecological pain among women that has considerable impact on quality of life and psychosocial wellbeing. Non-steroidal anti-inflammatory drugs (NSAIDs) an...
-
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-02 Yutaka Kuroda, Toshiyuki Kawai, Yaichiro Okuzu, Yugo Morita, Shuichi Matsuda
Osteonecrosis of the femoral head (ONFH) is arefractory disease requiring joint replacement in young patients. Regenerativetherapies have been developed.This study surveyed clinical trials onregene...
-
Investigational new drugs for the treatment of chronic renal failure: an overview of the literature Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-01 Chiara Terzo, Guido Gembillo, Valeria Cernaro, Elisa Longhitano, Vincenzo Calabrese, Chiara Casuscelli, Luigi Peritore, Domenico Santoro
Chronic kidney disease (CKD) is widespread throughout the world, with a high social and health impact. It is considered a ‘silent killer’ for its sudden onset without symptoms in the early stages o...
-
Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-01 Ernesto Maddaloni, Rocco Amendolara, Angela Balena, Alessandro Latino, Rosario Luigi Sessa, Raffaella Buzzetti
. Despite the improvements of insulin therapy, people with type 1 diabetes (T1D) still suffer from a decreased quality of life and life expectancy. The search toward a cure for T1D is therefore sti...
-
Current experimental and early investigational agents for cardiac fibrosis: where are we at? Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-03-01 Claudio M. Ciampi, Andrea Sultana, Paolo Ossola, Andrea Farina, Gabriele Fragasso, Roberto Spoladore
Myocardial fibrosis (MF) is induced by factors activating pro-fibrotic pathways such as acute and prolonged inflammation, myocardial ischemic events, hypertension, aging process, and genetically-li...
-
Early investigational agents for the treatment of benign prostatic hyperplasia’ Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-29 Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves
Benign prostatic hyperplasia (BPH), as a clinical entity that affects many people, has always been in the forefront of interest among researchers, pharmaceutical companies, and physicians. Patients...
-
Investigational pharmacological agents for the treatment of ARDS Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-27 Katyayini Aribindi, Michelle Lim, Satyan Lakshminrusimha, Timothy Albertson
Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that results in diffuse lung inflammation w...
-
A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-26 Andrew Leask, Asmaa Fadl, Angha Naik
The potent profibrotic cytokine transforming growth factor-β (TGF-β) has been associated with the onset and progression of the fibrosis seen in the autoimmune connective tissue disease scleroderma ...
-
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-26 Henriette Farkas, Zsuzsanna Balla
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent edema and predominantly caused by the dysregulation of the kinin-kallikrein system.This manuscript presents the res...
-
Correction Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-19
Published in Expert Opinion on Investigational Drugs (Vol. 33, No. 2, 2024)
-
The impact of current investigational drugs for acne on future treatment strategies Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-19 Heli A. Patel, Lily Guo, Steven R. Feldman
Acne vulgaris is one of the most prevalent diseases worldwide with a considerably high cost and a burden on quality of life. There are currently many topical and systemic therapies for acne; howeve...
-
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-23 Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi
Irritable bowel syndrome (IBS) has a significant impact on society and quality of life. Current treatments are ineffective, and new investigational drugs are necessary.Numerous potential therapies ...
-
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-23 Rafael Rosell, Carlos Pedraz-Valdunciel, Anisha Jain, Chandan Shivamallu, Andrés Aguilar
Targeted therapy is used to treat lung adenocarcinoma caused by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (<5%) of non-small cell lung cancer...
-
GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-23 Deanne H Hryciw, Rhiannon K Patten, Raymond J Rodgers, Joseph Proietto, Dana S Hutchinson, Andrew J McAinch
Type 2 diabetes (T2D) is metabolic disorder associated with a decrease in insulin activity and/or secretion from the β-cells of the pancreas, leading to elevated circulating glucose. Current manage...
-
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-23 Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt
Immune checkpoint inhibitors have achieved great success in the treatment of many different types of cancer. Programmed cell death protein ligand 1 (PD-L1, CD274) is a major immunosuppressive immun...
-
Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Paola Rogliani, Gian Marco Manzetti, Federica Roberta Bettin, Maria D’Auria, Luigino Calzetta
Severe asthma patients often remain uncontrolled despite high-intensity therapies. Biological therapies targeting thymic stromal lymphopoietin (TSLP), a key player in asthma pathogenesis, have emer...
-
KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-14 Carlo María Cicala, Iván Olivares-Rivas, Jon Ander Aguirre-Carrillo, César Serrano
Approximately 90% of gastrointestinal stromal tumors (GISTs) are driven by activating mutations in receptor tyrosine-kinases KIT or PDGFRA. Despite the outstanding results of first-line imatinib in...
-
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Katherine Y. Le, Michael Otto
Published in Expert Opinion on Investigational Drugs (Vol. 33, No. 1, 2024)
-
Potential of muvalaplin as a lipoprotein(a) inhibitor Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Amanda J. Hooper, P. Mihika S. Fernando, John R. Burnett
Published in Expert Opinion on Investigational Drugs (Vol. 33, No. 1, 2024)
-
Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Xiao-Jian Zhou, Steven S Good, Keith Pietropaolo, Qi Huang, Adel Moussa, Janet MJ Hammond, Jean-Pierre Sommadossi
Chronic hepatitis C virus (HCV) persists as a public health concern worldwide. Consequently, optimizing HCV therapy remains an important objective. While current therapies are generally highly effe...
-
Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Jenifer Sassarini, Richard A Anderson
Menopausal vasomotor symptoms (VMS) are experienced by most women and are often debilitating and can last for years. While hormone replacement therapy is effective, it carries risks that have impac...
-
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Eren Arslan Davulcu, Merve Beyza Oğuz, Emre Kılıç, Ahmet Emre Eşkazan
Myelofibrosis is a clonal myeloproliferative neoplasm associated with the proliferation of hematopoietic stem cells, increased bone marrow fibrosis, extramedullary hematopoiesis, hepatosplenomegaly...
-
Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Yimin Yu, Jingjing He, Zhiwei Huang, Yan Li, Ying Wu, Yifeng Shen, Yanling Zhou, Cungang Bao, Zhiping Jin, Huafang Li
JX11502MA is a potent partial agonist of dopamine D2 and D3 receptors, with a preferential binding profile for D3 receptors in vitro, potentially for treating schizophrenia.A first-in-human, random...
-
Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-12 Yicong Bian, Sheng Ma, Qingqing Yao, Tao Hu, Mingjing Ge, Hongting Li, Shansong Zheng, Zheming Gu, Hao Feng, Zhenwen Yu, Chenrong Huang, Hua Zhang, Limei Zhao, Liyan Miao
Iruplinalkib is a novel anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive crizotinib-resistant NSCLC.A single oral dose of 120 mg/3.7 MBq [14C]iruplinalkib was administer...
-
Duchenne muscular dystrophy: promising early-stage clinical trials to watch Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-06 Annie Tang, Toshifumi Yokota
Current therapies are unable to cure Duchenne muscular dystrophy (DMD), a severe and common form of muscular dystrophy, and instead aim to delay disease progression. Several treatments currently in...
-
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-05 Andrew Peel, R. Louise Rushworth, David J Torpy
Adrenal insufficiency currently affects over 300/million population, with higher morbidity and mortality compared to the general population. Current glucocorticoid replacement therapy is limited by...
-
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-02 Zheng Xian Thng, Jonathan Regenold, Albert John Bromeo, Amir Akhavanrezayat, Ngoc T.T. Than, Anadi Khatri, S. Saeed Mohammadi, Anh N.T. Tran, Yong Un Shin, Irmak Karaca, Hashem H. Ghoraba, Christopher Chi Mong Or, Quan Dong Nguyen
Uveitis is a heterogeneous group of ocular conditions characterized by inflammation of the uveal tract and is one of the leading causes of vision impairment. In developed countries, noninfectious u...
-
Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-02-01 Jacopo Simonetti, Marco Ficili, Giacomo Sgalla, Luca Richeldi
Idiopathic Pulmonary Fibrosis (IPF) is a progressive, irreversible, and fatal lung disease with unmet medical needs. Autotaxin (ATX) is an extracellular enzyme involved in the generation of lysopho...
-
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-01-31 Xingyu Zhou, Dong Xu, Mengtao Li, Xiaofeng Zeng
Sjögren’s syndrome is a heterogeneous autoimmune condition that impairs quality of life because of dryness, fatigue, pain, and systemic involvements. Current treatment largely depends on empirical ...
-
Progress in the treatment of anal cancer: an overview of the latest investigational drugs Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-01-30 James Yu, Richard D. Kim
Anal cancer, a rare malignancy accounting for 2.5–3.0% of gastrointestinal cancers, primarily manifests as squamous cell carcinoma associated with HPV. Recent years have witnessed significant advan...
-
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-01-29 Misako Nagasaka, Danielle Brazel, Sai-Hong Ignatius Ou
While crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC), unmet needs remain. These unmet needs include treatment options for pat...
-
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-01-26 Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile
Published in Expert Opinion on Investigational Drugs (Vol. 33, No. 2, 2024)
-
Islatravir: evaluation of clinical development for HIV and HBV Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2024-01-26 Samuel W. Gillespie, Athreya S. Reddy, Dana M. Burris, S. Hasan Naqvi, Siddappa N. Byrareddy, Christian L. Lorson, Kamal Singh
Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that inhibits HIV RT through multiple mechanisms. Contrary to all approved NtRTIs, islatravir retains a 3’OH g...
-
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders? Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Andrea Visentin, Marco Puthenparampil, Chiara Briani
Bruton’s tyrosine kinase (BTK) is a multifaceted player of the immune system which has been involved in the survival of hematological malignancies but also in the pathogenesis of immune-mediated di...
-
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Ashwin Ajay, Debar Rasoul, Alend Abdullah, Benjamin Lee Wei En, Knievel Mashida, Marwan Al-Munaer, Hanan Ajay, Dileep Duvva, Jean Mathew, Adeoye Adenaya, Gregory Y H Lip, Rajiv Sankaranarayanan
Heart failure is a complex, debilitating condition and despite advances in treatment, it remains a significant cause of morbidity and mortality worldwide. Therefore, the need for alternative treatm...
-
Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Pavan Khatkar, Jess C Hubbard, Lisa Hill, Alexandra J Sinclair, Susan P Mollan
Idiopathic intracranial hypertension is a neurological condition characterized by a raised intracranial pressure and papilledema that causes debilitating headaches. While the extent of the pathophy...
-
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Matthias Ocker, Daniel Neureiter
Liver fibrosis represents an unmet medical condition with growing incidence and only limited therapeutic options. Interfering with dysregulated gene expression was considered a specific treatment a...
-
Anti-inflammatory therapies for acute respiratory distress syndrome Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Denise Battaglini, Ida Giorgia Iavarone, Lou’i Al-Husinat, Lorenzo Ball, Chiara Robba, Pedro Leme Silva, Fernanda F. Cruz, Patricia RM Rocco
Treatments for the acute respiratory distress syndrome (ARDS) are mainly supportive, and ventilatory management represents a key approach in these patients. Despite progress in pharmacotherapy, ant...
-
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 Brian Dean
Successful phase 3 trials of KarXT in people with schizophrenia herald a new era of treating the disorder with drugs that do not target the dopamine D2 receptor. The active component of KarXT is xa...
-
Upamostat: a serine protease inhibitor for antiviral, gastrointestinal, and anticancer indications Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-12-28 TF. Plasse, R. Fathi, C. Fehrmann, GA. McComsey
Serine proteases are involved in many normal metabolic processes but also contribute to diseases of several organ systems, including viral and gastrointestinal diseases and oncology. Upamostat is a...
-
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Sylvia Boesch, Elisabetta Indelicato
Published in Expert Opinion on Investigational Drugs (Vol. 32, No. 11, 2023)
-
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen
Chronic hepatitis B infection is a major global health issue associated with significant liver-related morbidity and mortality. While existing treatments can suppress the virus effectively, they ar...
-
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Ayoola Awosika, Yoonje Cho, Ujjal Bose, Adekunle E. Omole, Uzochukwu Adabanya
Hypertension, a global health concern, poses a significant risk for other cardiovascular diseases. While lifestyle modifications and interventions like the Dietary Approaches to Stop Hypertension (...
-
Retatrutide showing promise in obesity (and type 2 diabetes) Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Sheila A Doggrell
Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polyp...
-
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Roger Auth, James R. Klinger
Pulmonary arterial hypertension (PAH) is a progressive and life-threatening disease. Approved treatment options currently primarily target abnormal cell signaling pathways involved in vasoconstrict...
-
Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Bettina Wedi
Chronic urticaria (CU), including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is a prevalent, enduring, mast-cell driven condition that presents challenges in its m...
-
Hepatic encephalopathy: investigational drugs in preclinical and early phase development Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Tiziano Balzano, Marta Llansola, Yaiza M. Arenas, Paula Izquierdo-Altarejos, Vicente Felipo
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome, in patients with liver disease, which affects life quality and span. Current treatments are lactulose or rifaximin, acting on gut microbi...
-
Developments and challenges for new and emergent preparations for male hypogonadism treatment Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Giovanni Corona, Clotilde Sparano, Giulia Rastrelli, Linda Vignozzi, Mario Maggi
The specific role of testosterone (T) replacement therapy in patients with late onset hypogonadism is still conflicting. Several available preparations have been developed to restore either fertili...
-
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Shuanzhi Wu, Tenghua Wang, Jieyun Li, Zhixin Zhang, Chen Li, Shuangshuang Xiao, Jin He, Xuan Wang, Zhiqin Hu, Xiaole Wang, Sichao Zheng, Xintong Liang, Guiying Chen, Yongmei Li, Xianbo Li, Yaoxuan Zhan, Qinwen Zou, Hongliang Jiang, Qingshan Zheng, Li Ban, Haiyan Liu, Yi Fang
SAR107375E is a direct dual inhibitor of both Factor Xa and Factor IIa and has shown potent anticoagulation activity in vitro and animals. This study evaluated the safety, tolerability, pharmacokin...
-
Retatrutide: a triple incretin receptor agonist for obesity management Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Avik Ray
Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management.Retatrutide, i...
-
Investigational drugs inhibiting complement for the treatment of geographic atrophy Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Lorenzo Ferro Desideri, Dmitri Artemiev, Enrico Bernardi, Karin Paschon, Souska Zandi, Martin Zinkernagel, Rodrigo Anguita
Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to severe visual impairment and central vision loss. Traditional treatment options for GA are limi...
-
Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-24 Sophia Moshegov, Nathan Mitchell Kerr
Glaucoma is a leading cause of blindness with intraocular pressure (IOP) as the only known modifiable risk factor. Prostaglandin FP receptor agonists are the first-line medical treatment for glauco...
-
Investigational treatment strategies in glioblastoma: progress made and barriers to success Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-06 Thomas A Nelson, Jorg Dietrich
Glioblastoma, isocitrate dehydrogenase wildtype (IDHwt), remains an incurable disease despite considerable research effort. The current standard of care since 2005 comprises maximal safe resection ...
-
NF1 alterations in cancers: therapeutic implications in precision medicine. Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-06 Jean-Stéphane Giraud,Ivan Bièche,Éric Pasmant,Camille Tlemsani
INTRODUCTION NF1 is a tumor suppressor gene encoding neurofibromin, an inhibitor of the RAS/MAPK and PI3K-AKT-mTOR signaling pathways. NF1 germline pathogenic variants cause the tumor predisposition syndrome neurofibromatosis type 1. Targeted therapies (MEK inhibitors) have been approved for benign nerve sheath tumors in neurofibromatosis type 1 patients. NF1 somatic alterations are present in ~5%
-
Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now? Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-06 Shingo Nakayamada, Yoshiya Tanaka
Glucocorticoids and immunosuppressants are used to treat systemic lupus erythematosus (SLE). However, patients with SLE have poor long-term prognoses. This can be attributed to organ damage caused ...
-
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects Expert Opin. Investig. Drugs (IF 6.1) Pub Date : 2023-11-06 Hyun A. Lee, Sujung Kim, Hyoryeong Seo, Soyeon Kim
SB16 is a biosimilar to reference denosumab (DEN). This study assessed pharmacokinetic (PK) equivalence and evaluated pharmacodynamic (PD), safety, tolerability, and immunogenicity between SB16, Eu...